Early steroid withdrawal in a renal transplant cohort treated with tacrolimus, mycophenolate mofetil and basiliximab

Nefrologia. 2014;34(2):216-22. doi: 10.3265/Nefrologia.pre2013.Dec.12028.
[Article in English, Spanish]

Abstract

Background: Acute rejection and graft function have not been completely clarified in early-steroid-withdrawal (ESW) patients. The objective of this study was to compare the effect of early steroid withdrawal on GFR, graft survival/rejection in recipients in a cohort treated with tacrolimus/mycophenolate mofetil compared to a control cohort.

Material and method: Retrospective cohort, in 60 low immunological risk recipients between December 2005 and July 2010. Study cohort (ESW-C N=32), steroid withdrawal was carried out after 5 days, while they were receiving tacrolimus/mycophenolate mofetil. The control cohort (C-C, N=28) received prednisone/tacrolimus/mycophenolate mofetil. Clinical, biochemical and histological variables were assessed at baseline and after 3, 6, and 12 months of follow-up. Kaplan-Meier and the Cox proportional hazards model were used to assess survival. Comparisons between cohorts were carried out by the Student's t and c2 tests.

Results: At follow-up, C-C displayed significantly higher systolic (125 ± 10 vs. 114 ± 8) and diastolic (81 ± 8 vs. 72 ± 7) blood pressure, serum glucose (96 ± 13 vs. 86 ± 10), triglycerides (177 ± 61 vs. 129 ± 34), total (183 ± 43 vs. 148 ± 34) and LDL-cholesterol (100 ± 22 vs. 87 ± 25). C-C had a higher proportion of antihypertensive (57 vs. 13%), and statins (27 vs. 9%) use. eGFR was better in ESW-C than in C-C (85.4 ± 20.6 vs. 70.6 ± 17.0, p=.004). AR frequency was lower in ESW-C.

Conclusions: Graft survival, GFR, AR rate and metabolic profile were better in the ESW-C than in C-C.

Publication types

  • Evaluation Study

MeSH terms

  • Adult
  • Antibodies, Monoclonal / therapeutic use*
  • Basiliximab
  • Cohort Studies
  • Drug Therapy, Combination
  • Female
  • Glomerular Filtration Rate / physiology
  • Glucocorticoids* / therapeutic use
  • Graft Rejection / epidemiology
  • Graft Survival
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Kidney Transplantation*
  • Male
  • Mycophenolic Acid / analogs & derivatives*
  • Mycophenolic Acid / therapeutic use
  • Prednisone* / therapeutic use
  • Recombinant Fusion Proteins / therapeutic use*
  • Retrospective Studies
  • Tacrolimus / therapeutic use*
  • Time Factors
  • Withholding Treatment

Substances

  • Antibodies, Monoclonal
  • Glucocorticoids
  • Immunosuppressive Agents
  • Recombinant Fusion Proteins
  • Basiliximab
  • Mycophenolic Acid
  • Prednisone
  • Tacrolimus